Express Pharma

Moderna COVID vaccine sales forecasts fall short for 2022, 2023

The company did say the 2023 outlook excludes expected contracts with countries such as the US and Japan, and that it anticipated the forecast to be the "floor" for next year's sales

0 132

Moderna yesterday cut its 2022 COVID-19 vaccine sales forecast, citing regulatory and production delays, and issued a 2023 outlook for the shots well below Wall Street estimates, and its shares fell as much as nine per cent before recovering.

It expects $4.5 billion to $5.5 billion in sales from signed COVID vaccine contracts for the next year, while analysts’ estimates were at $9.5 billion.

That forecast comes despite the company delaying up to $3 billion worth of 2022 vaccine sales it would now deliver in 2023 due to quality control issues at its contract manufacturing partner. The company did say the 2023 outlook excludes expected contracts with countries such as the Us and Japan, and that it anticipated the forecast to be the “floor” for next year’s sales.

Demand for COVID vaccines has waned globally. Moderna agreed earlier this year to push back deliveries on its contract with the European Union to late 2022 or early 2023. It also cancelled an existing deal with vaccine alliance GAVI, and struck a new deal to instead to supply the organisation up to 100 million doses of its updated booster vaccine in 2023 for some of the world’s poorest countries.

Moderna’s new sales forecast comes after Pfizer said it plans to quadruple the price of its COVID-19 shot once the US moves away from government funding to a private market for COVID-19 vaccines next year.

Moderna declined to answer questions on a new US price during a conference call to discuss third-quarter results. The company said the private market could be unpredictable and that vaccine deliveries might become seasonal, such as with flu shots.

“We anticipate a more fragmented customer base, including private payers, health plans, pharmacy chains, individual pharmacies and physician offices,” said Arpa Garay, Chief Commercial Officer, Moderna. “We also anticipate reduced predictability in orders.”

Along with production delays, Moderna’s third quarter was marred with manufacturing complexities due to shifting from 10-dose vials to five-dose vials and the roll out of new bivalent vaccines that target both the original coronavirus and Omicron variants, Stephane Bancel, Chief Executive, said.